Overcoming Patient Barriers to Initiating Insulin Therapy in Type 2 Diabetes Mellitus

Clinical Cornerstone

Volumn 9, Issue 2, 2008, Pages 63-73

  Marrero, David G ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

GLIBENCLAMIDE; GLUCOSE; HEMOGLOBIN A1C; INSULIN; INSULIN ASPART; INSULIN GLARGINE; ISOPHANE INSULIN; METFORMIN; ORAL ANTIDIABETIC AGENT; SULFONYLUREA;

ADD ON THERAPY; ARTICLE; BEDTIME DOSAGE; CLINICAL TRIAL; DIABETES MELLITUS; DISEASE SEVERITY; DOCTOR PATIENT RELATION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SAFETY; EVIDENCE BASED MEDICINE; FEAR; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEALTH CARE ACCESS; HEALTH CARE AVAILABILITY; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN RELEASE; LIFESTYLE MODIFICATION; MORNING DOSAGE; NEEDLE; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; PANCREAS ISLET CELL FUNCTION; PATIENT ATTITUDE; PATIENT COMPLIANCE; PATIENT COUNSELING; PATIENT EDUCATION; QUALITY OF LIFE; SIDE EFFECT; WEIGHT GAIN;

ATTITUDE TO HEALTH; DIABETES MELLITUS, TYPE 2; FEAR; HUMANS; HYPOGLYCEMIC AGENTS; INJECTIONS; INSULIN; MEDICATION ADHERENCE; NEEDLES;

EID: 65349168854     PISSN: 10983597     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1098-3597(09)62041-X     Document Type: Article

References (28)

1. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352 (1998) 837-853
2. UK Prospective Diabetes Study (UKPDS) 16. Overview of 6 years' therapy of type II diabetes: A progressive disease [published correction appears in Diabetes. 1996:45:1655]. Diabetes 44 (1995) 1249-1258
3. Wright A., Burden A.C., Paisey R.B., et al. Sulfonylurea inadequacy: Efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57) [published correction appears in Diabetes Care. 2002;25:1268]. Diabetes Care 25 (2002) 330-336
4. Riddle M.C. The underuse of insulin therapy in North America. Diabetes Metab Res Rev 18 Suppl 3 (2002) S42-S49
5. Scarlett J.A., Gray R.S., Griffin J., et al. Insulin treatment reverses the insulin resistance of type II diabetes mellitus. Diabetes Care 5 (1982) 353-363
6. Andrews W.J., Vasquez B., Nagulesparan M., et al. Insulin therapy in obese, non-insulin-dependent diabetes induces improvements in insulin action and secretion that are maintained for two weeks after insulin withdrawal. Diabetes 33 (1984) 634-642
7. Garvey W.T., Olefsky J.M., Griffin J., et al. The effect of insulin treatment on insulin secretion and insulin action in type II diabetes mellitus. Diabetes 34 (1985) 222-234
8. Brown J.B., Nichols G.A., and Perry A. The burden of treatment failure in type 2 diabetes. Diabetes Care 27 (2004) 1535-1540
9. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 28 Suppl 1 (2005) S4-S36
10. American Association of Clinical Endocrinologists Medical Guidelines for the Management of Diabetes Mellitus. The AACE System of Intensive Diabetes Self-Management-2002 Update. Endocr Pract 8 Suppl 1 (2002) 43-56
11. Peyrot M., Rubin R.R., Lauritzen T., et al. Resistance to insulin therapy among patients and providers. Results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study. Diabetes Care 28 (2005) 2673-2679
12. Diabetes Attitudes, Wishes, and Needs (DAWN) Study. Barriers to treatment. Available at: http://www.dawnstudy.com Accessed January 30, 2007.
13. Koro C.E., Bowlin S.J., Bourgeois N., and Fedder D.O. Glycemic control from 1988 to 2000 among U.S. adults diagnosed with type 2 diabetes. A preliminary report. Diabetes Care 27 (2004) 17-20
14. Reeves M.J., and Rafferty A.P. Healthy lifestyle characteristics among adults in the United States, 2000. Arch Intern Med 165 (2005) 854-857
15. Chapman R.H., Benner J.S., Petrilla A.A., et al. Predictors of adherence with antihypertensive and lipid-lowering therapy. Arch Intern Med 165 (2005) 1147-1152
16. Cramer J.A. A systematic review of adherence with medications for diabetes. Diabetes Care 27 (2004) 1218-1224
17. Marrero DG, Monahan PO, Lane KA, Hayes RP. Validation of a scale to measure patient-perceived barriers to medication use. 2006 International Society for Quality of Life Research meeting abstracts. [www.isoqol.org/2006mtgabstracts]. The QLR Journal. 2006:A-34-A-35. Abstract #1223.
18. Polonosky W.H., and Jackson R.A. What's so tough about taking insulin? Addressing the problem of psychological insulin resistance in type 2 diabetes. Clin Diabetes 22 (2004) 147-150
19. Polonosky W.H., Fisher L., Guzman S., et al. Psychological insulin resistance in patients with type 2 diabetes. The scope of the problem. Diabetes Care 28 (2005) 2543-2545
20. Funnell M.M., Kruger D.F., and Spencer M. Self-management support for insulin therapy in type 2 diabetes. Diabetes Educator 30 (2004) 274-280
21. Exubera® (insulin human [rDNA origin]). Inhalation Powder. Available at: http://www.exubera.com Accessed March 14, 2007.
22. Riddle M.C., Rosenstock J., Gerich J., et al. The Treat-to-Target Trial. Randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 26 (2003) 3080-3086
23. Yki-Jarvinen H., Dressler A., and Ziemen M. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. Diabetes Care 23 (2000) 1130-1136
24. Janka H.U., Plewe G., Riddle M.C., et al. Comparison of basal insulin added to oral agents versus twice-daily pre-mixed insulin as initial insulin therapy for type 2 diabetes. Diabetes Care 28 (2005) 254-259
25. Raskin P., Allen E., Hollander P., et al. Initiating insulin therapy in type 2 diabetes. Diabetes Care 28 (2005) 260-265
26. Yki-Jarvinen H., Ryysy L., Nikkila K., et al. Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus. A randomized, controlled trial. Ann Intern Med 130 (1999) 389-396
27. Aviles-Santes L., Sinding J., and Raskin P. Effects of metformin in patients with poorly controlled, insulin-treated type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 131 (1999) 182-188
28. Vijan S., Hayward R.A., Ronish D.L., and Hofer T.P. The burden of diabetes therapy: Implications for the design of effective patient-centered treatment regimens. J Gen Intern Med 20 (2005) 479-482